Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets.

Nature chemical biology - 1 Aug 2014

Kasap Corynn, Elemento Olivier, Kapoor Tarun M

Abstract excerpt

To identify physiological targets of drugs and bioactive small molecules, we developed an approach, named DrugTargetSeqR, which combines high-throughput sequencing, computational mutation discovery and clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9-based genome editing. W...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Naphthoquinones
Share to Benzamides
Share to Clustered Regularly Interspaced Short Palindromic Repeats

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endonucleases

Share to Imidazoles

Share to Kinesins

Share to Molecular Targeted Therapy

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 24929528
DOI: 10.1038/nchembio.1551
PMCID: PMC4123312

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Prepared record publication-24929528-2026-09-05.1. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets.PMID 24929528Read ↗

Identifying chemogenetic interactions from CRISPR knockout screens with drugZSemantic proximity Read ↗

enAsCas12a Enables CRISPR-Directed Evolution to Screen for Functional Drug Resistance Mutations in Sequences Inaccessible to SpCas9.Semantic proximity Read ↗

CRISPR-Suppressor Scanning for Systematic Discovery of Drug-Resistance Mutations.Semantic proximity Read ↗

Identifying chemogenetic interactions from CRISPR screens with drugZSemantic proximity Read ↗

A Chemical-Genetic Interaction Matrix Reveals Drug Mechanism and Genetic ArchitectureSemantic proximity Read ↗

New strategies for targeting drug combinations to overcome mutation-driven drug resistance.Semantic proximity Read ↗

A CRISPR-drug perturbational map for identifying new compounds to combine with commonly used chemotherapeuticsSemantic proximity Read ↗

Methods and resources to access mutation-dependent effects on cancer drug treatment.Semantic proximity Read ↗

Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label therapySemantic proximity Read ↗

Advances in Genomics for Drug Development.Semantic proximity Read ↗

A scalable platform for efficient CRISPR-Cas9 chemical-genetic screens of DNA damage-inducing compoundsSemantic proximity Read ↗

Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.